Journal of Clinical & Experimental Immunology(JCEI)
ISSN: 2475-6296 | DOI: 10.33140/JCEI
Impact Factor: 1.9
Time to Cardiovascular Complications and Associated Factors among Hypertensive Patients under treatment at Government Hospitals in Amhara Region
Abstract
Awoke Seyoum Tegegne
Background Cardiovascular disease complication is a current public issue throughout the world. This study aimed to investigate the time to cardiovascular complication and associated factors among hypertensive patients under treatment at government Hospitals in Amhara region, North-West Ethiopia.
Methods A retrospective cohort study design was conducted on 1014 hypertensive patients. The data were secondary and had been taken from a chart of each patient, recorded at government hospitals in Amhara region, Ethiopia, whose follow ups were from 2018 to 2023.
Result Among the predictors, baseline complication significantly affected the variable of interest in the current study. Hence, the risk of developing cardiovascular disease complications for patients, who had baseline complications, was 4.684 times that of patients without baseline complications (P-value= 0.0004). The hazard of hypertensive patients who had related disease was 2.437 times that of patients without the related disease (p-value ≤ 0.001). Smoking status also significantly affected the event in this study which indicates that the Expected hazard of developing cardiovascular disease complications for a smoker patient was 3.463 times that of a non-smoker patient (p-value ≤ 0.001). The hazard of developing cardiovascular disease complication for stage 2 hypertensive patients was 3.406 times that of stage 1 patients (P-value= 0.012).
Conclusions The result of the Cox proportional hazard model indicates that baseline complications, the existence of the related disease, smoking status, and stage of hypertension significantly affected cardiovascular disease complications of hypertensive patients at a 5% significance level. Due attention should be given to smoker hypertensive patients, hypertensive patients with baseline complications, hypertensive patients with related disease and hypertensive patients of stage 2.